<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Rheumatology</title>
    <link>http://repub.eur.nl/res/org/9823/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH) (Article)</title>
      <link>http://repub.eur.nl/res/pub/24028/</link>
      <pubDate>2011-05-27T00:00:00Z</pubDate>
      <description>
        
        Introduction: An ACR/EULAR task force released new criteria to classify rheumatoid arthritis at an early stage. This study evaluates the diagnostic performance of these criteria and algorithms by van der Helm and Visser in REACH. Methods: Patients with symptoms ≤12 months from REACH were used. Algorithms were tested on discrimination, calibration and diagnostic accuracy of proposed cut-points. Two patient sets were defi ned to test robustness; undifferentiated arthritis (UA) (n=231) and all patients including those without synovitis (n=513). The outcomes evaluated were methotrexate use and persistent disease at 12 months. Results: In UA patients all algorithms had good areas under the curve 0.79, 95% CI 0.73 to 0.83 for the ACR/EULAR criteria, 0.80, 95% CI 0.74 to 0.87 for van der Helm and 0.83, 95% CI 0.77 to 0.88 for Visser. All calibrated well. Sensitivity and specifi city were 0.74 and 0.66 for the ACR/EULAR criteria, 0.1 and 1.0 for van der Helm and 0.59 and 0.93 for Visser. Similar results were found in all patients indicating robustness. Conclusion: The ACR/EULAR 2010 criteria showed good diagnostic properties in an early arthritis cohort refl ecting daily practice, as did the van der Helm and Visser algorithms. All were robust. To promote uniformity and comparability the ACR/EULAR 2010 criteria should be used in future diagnostic studies. Copyright Article author (or their employer) 2011.
      </description>
      <author>Alves, C.</author> <author>Luime, J.J.</author> <author>Zeben, D. van</author> <author>Huisman, M.A.M.</author> <author>Weel, A.E.A.M.</author> <author>Barendregt, P.J.</author> <author>Hazes, J.M.W.</author>
    </item> <item>
      <title>Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening (Article)</title>
      <link>http://repub.eur.nl/res/pub/25905/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>
        
        Aim: To determine the inter-observer variation in the histological diagnosis of colorectal polyps. Methods and results: Four hundred and forty polyps were randomly selected from a colorectal cancer screening programme. Polyps were first evaluated by a general (324 polyps) or expert (116 polyps) pathologist, and subsequently re-evaluated by an expert pathologist. Conditional agreement was reported, and inter-observer agreement was determined using kappa statistics. In 421/440 polyps (96%), agreement for their non-adenomatous or adenomatous nature was obtained, corresponding to a very good kappa value of 0.88. For differentiation of adenomas as non-advanced and advanced, consensus was obtained in 266/322 adenomas (83%), with a moderate kappa value of 0.58. For the non-adenomatous or adenomatous nature, both general and expert pathologists, and expert pathologists between each other, showed very good agreement {kappa values of 0.89 [95% confidence interval (CI) 0.83-0.95] and 0.86 (95% CI 0.73-0.98), respectively}. For categorization of adenomas as non-advanced and advanced, moderate agreement was found between general and expert pathologists, and between expert pathologists [kappa values of 0.56 (95% CI 0.44-0.67) and 0.64 (95% CI 0.43-0.85), respectively]. Conclusions: General and expert pathologists demonstrate very good inter-observer agreement for differentiating non-adenomas from adenomas, but only moderate agreement for non-advanced and advanced adenomas. The considerable variation in differentiating non-advanced and advanced adenomas suggests that more objective criteria are required for risk stratification in screening and surveillance guidelines. 
      </description>
      <author>Putten, P. van</author> <author>Hol, L.</author> <author>Dekken, H. van</author> <author>Krieken, J.H.J.M. van</author> <author>Ballegooijen, M. van</author> <author>Kuipers, E.J.</author> <author>Leerdam, M.E. van</author>
    </item> <item>
      <title>Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening (Article)</title>
      <link>http://repub.eur.nl/res/pub/26389/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>
        
        Aim: To determine the inter-observer variation in the histological diagnosis of colorectal polyps. Methods and results: Four hundred and forty polyps were randomly selected from a colorectal cancer screening programme. Polyps were first evaluated by a general (324 polyps) or expert (116 polyps) pathologist, and subsequently re-evaluated by an expert pathologist. Conditional agreement was reported, and inter-observer agreement was determined using kappa statistics. In 421/440 polyps (96%), agreement for their non-adenomatous or adenomatous nature was obtained, corresponding to a very good kappa value of 0.88. For differentiation of adenomas as non-advanced and advanced, consensus was obtained in 266/322 adenomas (83%), with a moderate kappa value of 0.58. For the non-adenomatous or adenomatous nature, both general and expert pathologists, and expert pathologists between each other, showed very good agreement {kappa values of 0.89 [95% confidence interval (CI) 0.83-0.95] and 0.86 (95% CI 0.73-0.98), respectively}. For categorization of adenomas as non-advanced and advanced, moderate agreement was found between general and expert pathologists, and between expert pathologists [kappa values of 0.56 (95% CI 0.44-0.67) and 0.64 (95% CI 0.43-0.85), respectively]. Conclusions: General and expert pathologists demonstrate very good inter-observer agreement for differentiating non-adenomas from adenomas, but only moderate agreement for non-advanced and advanced adenomas. The considerable variation in differentiating non-advanced and advanced adenomas suggests that more objective criteria are required for risk stratification in screening and surveillance guidelines. 
      </description>
      <author>Putten, P. van</author> <author>Hol, L.</author> <author>Dekken, H. van</author> <author>Krieken, J.H.J.M. van</author> <author>Ballegooijen, M. van</author> <author>Kuipers, E.J.</author> <author>Leerdam, M.E. van</author>
    </item> <item>
      <title>Pregnancy and reproduction in autoimmune rheumatic diseases (Article)</title>
      <link>http://repub.eur.nl/res/pub/23906/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>
        
        Despite evidence for the important role of oestrogens in the aetiology and pathophysiology of chronic immune/inflammatory diseases, the previous view of an unequivocal beneficial effect of oestrogens on RA compared with a detrimental effect on SLE has to be reconsidered. Likewise, the long-held belief that RA remits in the majority of pregnant patients has been challenged, and shows that only half of the patients experience significant improvement when objective disease activity measurements are applied. Pregnancies in patients with SLE are mostly successful when well planned and monitored interdisciplinarily, whereas a small proportion of women with APS still have adverse pregnancy outcomes in spite of the standard treatment. New prospective studies indicate better outcomes for pregnancies in women with rare diseases such as SSc and vasculitis. Fertility problems are not uncommon in patients with rheumatic disease and need to be considered in both genders. Necessary therapy, shortly before or during the pregnancy, demands taking into account the health of both mother and fetus. Long-term effects of drugs on offspring exposed in utero or during lactation is a new area under study as well as late effects of maternal rheumatic disease on children. 
      </description>
      <author>Ostensen, M.</author> <author>Brucato, A.</author> <author>Lockshin, M.D.</author> <author>Matucci-Cerinic, M.</author> <author>Meroni, P.</author> <author>Nelson, J.L.</author> <author>Parke, A.</author> <author>Petri, M.</author> <author>Raio, L.</author> <author>Ruiz-Irastorza, G.</author> <author>Silva, C.A.</author> <author>Tincani, A.</author> <author>Carp, H.</author> <author>Villiger, P.M.</author> <author>Wunder, D.</author> <author>Cutolo, M.</author> <author>Chambers, C.</author> <author>Dolhain, R.J.E.M.</author> <author>Doria, A.</author> <author>Förger, F.</author> <author>Jayson, G.C.</author> <author>Lee, H.S.</author> <author>Khamashta, M.</author>
    </item> <item>
      <title>A high physical workload and high job demands hamper the good prognosis in physical functioning in persons with early inflammatory joint conditions (Article)</title>
      <link>http://repub.eur.nl/res/pub/25146/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>
        
        Objective: To determine the influence of job characteristics on the prognosis of patients with early inflammatory joint conditions. Methods: In a prospective cohort study of 210 workers with inflammatory joint conditions present for &lt;12 months, data were collected by questionnaires and medical examination at baseline and after 6 and 12 months. Outcomes were self-reported pain and physical functioning, and the presence of at least one swollen joint. Generalized estimation equations were used to study the influence of job characteristics on prognosis in pain and function, and logistic regression analysis to study prognosis in swollen joints. Results: Pain and physical functioning strongly improved during the first 6-month period (40 and 14%, respectively), and improvement slowed considerably in the second 6-month period. The proportion of workers with swollen joints dramatically decreased from 58 to 20 then 7%. The good prognosis in pain and physical functioning in the first 6 months was hampered by persistent high levels of inflammation, older age, low perceived health control and low social support. Job characteristics had no influence on the prognosis of pain and swollen joints, whereas workers with frequent manual material handling or high job demands improved ~50% less in physical functioning. Conclusions: Job characteristics had no influence on the disease characteristics pain and swollen joints, but strongly affected the consequences of disease in physical functioning. Among patients with early inflammatory joint conditions, who do not recover in functional abilities, adjustments in working conditions may be imperative. 
      </description>
      <author>Geuskens, G.A.</author> <author>Burdorf, A.</author> <author>Barendregt, P.J.</author> <author>Hazes, J.M.W.</author>
    </item> <item>
      <title>Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: A case control study (Article)</title>
      <link>http://repub.eur.nl/res/pub/23993/</link>
      <pubDate>2011-03-07T00:00:00Z</pubDate>
      <description>
        
        Background: Various cytokines and inflammatory mediators are known to be involved in the pathogenesis of rheumatoid arthritis (RA). We hypothesized that polymorphisms in selected inflammatory response and tissue repair genes contribute to the susceptibility to and severity of RA.Methods: Polymorphisms in TNFA, IL1B, IL4, IL6, IL8, IL10, PAI1, NOS2a, C1INH, PARP, TLR2 and TLR4 were genotyped in 376 Caucasian RA patients and 463 healthy Caucasian controls using single base extension. Genotype distributions in patients were compared with those in controls. In addition, the association of polymorphisms with the need for anti-TNF-α treatment as a marker of RA severity was assessed.Results: The IL8 781 CC genotype was associated with early onset of disease. The TNFA -238 G/A polymorphism was differentially distributed between RA patients and controls, but only when not corrected for age and gender. None of the polymorphisms was associated with disease severity.Conclusions: We here report an association between IL8 781 C/T polymorphism and age of onset of RA. Our findings indicate that there might be a role for variations in genes involved in the immune response and in tissue repair in RA pathogenesis. Nevertheless, additional larger genomic and functional studies are required to further define their role in RA. 
      </description>
      <author>Emonts, M.</author> <author>Hazes, J.M.W.</author> <author>Houwing-Duistermaat, J.J.</author> <author>Jongh, C.E. de</author> <author>Vogel, L. de</author> <author>Han, K.H.</author> <author>Wouters, J.M.G.W.</author> <author>Laman, J.D.</author> <author>Dolhain, R.J.E.M.</author>
    </item> <item>
      <title>Complicated systemic lupus erythematosus pancreatitis: Pseudocyst, pseudoaneurysm, but real bleeding (Article)</title>
      <link>http://repub.eur.nl/res/pub/26014/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>
        
        We report the case of a 25-year-old patient with systemic lupus erythematosus (SLE) pancreatitis which was complicated by pseudocyst and pseudoaneurysm formation. The pseudoaneurysm progressed to intra-abdominal bleeding requiring endovascular coil embolization of the gastroduodenal artery. The pseudocyst and hematoma formed two large abdominal fluid collections causing symptoms due to a mass effect. These fluid collections were treated conservatively, while active SLE was treated with steroids, azathioprine, and immunoglobulins. She finally made a full recovery. To the best of our knowledge, this is the first report of a bleeding pseudoaneurysm complicating SLE pancreatitis. Although anecdotal, this case may serve as a useful example of the possible complications of SLE pancreatitis, including considerations on optimal management. Lupus (2011) 20, 305-307. 
      </description>
      <author>Hoorn, E.J.</author> <author>Flink, H.J.</author> <author>Kuipers, E.J.</author> <author>Poley, J.W.</author> <author>Mensink, P.B.F.</author> <author>Dolhain, R.J.E.M.</author>
    </item> <item>
      <title>Distribution of signs and symptoms of Complex Regional Pain Syndrome type I in patients meeting the diagnostic criteria of the International Association for the Study of Pain (Article)</title>
      <link>http://repub.eur.nl/res/pub/23296/</link>
      <pubDate>2011-02-21T00:00:00Z</pubDate>
      <description>
        
        The aim of the present study was to describe the occurrence of signs and symptoms in CRPS I patients meeting the IASP (Orlando) criteria, assess the occurrence of signs and symptoms in relation to disease duration and compare these to historical data based on a different diagnostic criteria set. Six hundred and ninety-two ambulatory patients meeting the IASP criteria for CRPS I referred to the outpatient clinics of five participating centers were included in this cross-sectional study. Characteristics were recorded in a standardized fashion and categorized according to the factor structure proposed by Bruehl/Harden. Subgroups were classified according to the duration of complaints and compared to historical data as described by Veldman et al. The Chi-square test corrected for multiple comparisons was used for statistical analysis. The prevalence of sensory signs was higher in patients with longer disease duration, especially for the allodynia's and hyperalgesia (all p &lt; 0.001). Signs in vasomotor (color difference; p = 0.0007) and sudomotor (edema; p &lt; 0.0001) subgroups were less frequently present in patients with longer disease duration (i.e. &gt;6 months). Prevalences of signs in the motor subgroup were all higher (p &lt; 0.0001) in patients with longer disease duration, except for limited range of motion. Occurrence of signs was significantly lower (&lt;0.001) than those reported by Veldman et al., except for hyperesthesia and dystonia. Occurrence rates may vary at different time points after onset of CRPS, which may be of influence for diagnosing patients with novel derived diagnostic criteria. We argue for a mechanism based description of CRPS I based on one set of uniform generally accepted diagnostic criteria in future studies.
      </description>
      <author>Boer, R.D.H. de</author> <author>Marinus, J.</author> <author>Hilten, J.J. van</author> <author>Huygen, F.J.P.M.</author> <author>Eijs, F. de</author> <author>Kleef, M. van</author> <author>Bauer, M.C.R.</author> <author>Gestel, M. van</author> <author>Zuurmond, W.W.A.</author> <author>Perez, R.S.G.M.</author>
    </item> <item>
      <title>Reply (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/21308/</link>
      <pubDate>2010-10-01T00:00:00Z</pubDate>
      <description>
        
        
      </description>
      <author>Colin, E.M.</author> <author>Hamburg, J.P. van</author> <author>Lubberts, E.</author>
    </item> <item>
      <title>2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative (Article)</title>
      <link>http://repub.eur.nl/res/pub/27297/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>
        
        Objective: The 1987 American College of Rheumatology (ACR; formerly the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticised for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA. Methods: A joint working group from the ACR and the European League Against Rheumatism developed, in three phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/ or erosive disease - this being the appropriate current paradigm underlying the disease construct 'RA'. Results: In the new criteria set, classification as 'definite RA' is based on the confirmed presence of synovitis in at least one joint, absence of an alternative diagnosis better explaining the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in four domains: number and site of involved joints (range 0-5), serological abnormality (range 0-3), elevated acute-phase response (range 0-1) and symptom duration (two levels; range 0-1). Conclusion: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimise the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct 'RA'.
      </description>
      <author>Aletaha, D.</author> <author>Neogi, T.</author> <author>Combe, B.</author> <author>Costenbader, K.H.</author> <author>Dougados, M.</author> <author>Emery, P.</author> <author>Ferraccioli, G.</author> <author>Hazes, J.M.W.</author> <author>Hobbs, K.</author> <author>Huizinga, T.W.J.</author> <author>Kavanaugh, A.</author> <author>Kay, J.</author> <author>Silman, A.J.</author> <author>Kvien, T.K.</author> <author>Laing, T.</author> <author>Mease, P.</author> <author>Ménard, H.A.</author> <author>Moreland, L.W.</author> <author>Naden, R.L.</author> <author>Pincus, T.</author> <author>Smolen, J.S.</author> <author>Stanislawska-Biernat, E.</author> <author>Symmons, D.</author> <author>Funovits, J.</author> <author>Tak, P.P.</author> <author>Upchurch, K.S.</author> <author>Vencovský, J.</author> <author>Wolfe, F.</author> <author>Hawker, G.</author> <author>Felson, D.</author> <author>Bingham, C.O.</author> <author>Birnbaum, N.S.</author> <author>Burmester, G.R.</author> <author>Bykerk, V.P.</author> <author>Cohen, M.D.</author>
    </item> <item>
      <title>The 2010 American College of Rheumatology/European league against rheumatism classification criteria for rheumatoid arthritis: Methodological report phase I (Article)</title>
      <link>http://repub.eur.nl/res/pub/27389/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>
        
        Objective: To apply a data-driven approach to investigate, in patients newly presenting with undifferentiated inflammatory synovitis, key variables that discriminate the subset of patients at sufficiently high risk of persistent or erosive disease for the purpose of developing new criteria for rheumatoid arthritis (RA). Methods: In this first phase of the collaborative effort of the American College of Rheumatology and European League Against Rheumatism to develop new criteria for RA, a pooled analysis of early arthritis cohorts made available by the respective investigators is presented. All the variables associated with the gold standard of treatment with methotrexate during the first year after enrolment were first identified. Principal component analysis was then used to identify among the significant variables those sets that represent similar domains. In a final step, from each domain one representative variable was extracted, all of which were then tested for their independent effects in a multivariate regression model. From the OR in that final model, the relative weight of each variable was estimated. Results The final domains and variables identified by this process (and their relative weights) were: swelling of a metacarpophalangeal joint (MCP; 1.5), swelling of a proximal interphalangeal joint (PIP; 1.5), swelling of the wrist (1.5), tenderness of the hand (ie, MCP, PIP or wrist (2)), acute phase reaction (ie, C reactive protein or erythrocyte sedimentation rate and weights for moderate or high elevations of either one (1 for moderate, 2 for high elevation)) and serological abnormalities (ie, rheumatoid factors or anti-citrullinated protein antibodies, again with separate weights for moderate or high elevations (2 and 4, respectively)). Conclusion: The results of this first phase were subsequently used in the second phase of the project, which is reported in a separate methodological paper, and for derivation of the final set of criteria.
      </description>
      <author>Funovits, J.</author> <author>Aletaha, D.</author> <author>Kay, J.</author> <author>Kvien, T.K.</author> <author>Smolen, J.S.</author> <author>Symmons, D.</author> <author>Tak, P.P.</author> <author>Silman, A.J.</author> <author>Bykerk, V.P.</author> <author>Combe, B.</author> <author>Dougados, M.</author> <author>Emery, P.</author> <author>Felson, D.</author> <author>Hawker, G.</author> <author>Hazes, J.M.W.</author> <author>Huizinga, T.W.J.</author>
    </item> <item>
      <title>2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative (Article)</title>
      <link>http://repub.eur.nl/res/pub/27427/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>
        
        Objective. The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA. Methods. A joint working group from the ACR and the European League Against Rheumatism developed, in 3 phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease - this being the appropriate current paradigm underlying the disease construct "rheumatoid arthritis." Results. In the new criteria set, classification as "definite RA" is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom duration (2 levels; range 0-1). Conclusion. This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimize the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct "rheumatoid arthritis." 
      </description>
      <author>Aletaha, D.</author> <author>Neogi, T.</author> <author>Combe, B.</author> <author>Costenbader, K.H.</author> <author>Dougados, M.</author> <author>Emery, P.</author> <author>Ferraccioli, G.</author> <author>Hazes, J.M.W.</author> <author>Hobbs, K.</author> <author>Huizinga, T.W.J.</author> <author>Kavanaugh, A.</author> <author>Kay, J.</author> <author>Silman, A.J.</author> <author>Kvien, T.K.</author> <author>Laing, T.</author> <author>Mease, P.</author> <author>Ménard, H.A.</author> <author>Moreland, L.W.</author> <author>Naden, R.L.</author> <author>Pincus, T.</author> <author>Smolen, J.S.</author> <author>Stanislawska-Biernat, E.</author> <author>Symmons, D.</author> <author>Funovits, J.</author> <author>Tak, P.P.</author> <author>Upchurch, K.S.</author> <author>Vencovský, J.</author> <author>Wolfe, F.</author> <author>Hawker, G.</author> <author>Felson, D.</author> <author>Bingham, C.O.</author> <author>Birnbaum, N.S.</author> <author>Burmester, G.R.</author> <author>Bykerk, V.P.</author> <author>Cohen, M.D.</author>
    </item> <item>
      <title>Does the intraclass correlation coefficient always reliably express reliability? Comment on the article by Cheung et al (Article)</title>
      <link>http://repub.eur.nl/res/pub/27459/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>
        
        
      </description>
      <author>Cate, D.F. ten</author> <author>Luime, J.J.</author> <author>Hazes, J.M.W.</author> <author>Jacobs, J.W.G.</author> <author>Landewé, R.</author>
    </item> <item>
      <title>The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report (Article)</title>
      <link>http://repub.eur.nl/res/pub/27651/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>
        
        Objective. The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set. Methods. Twenty-four expert RA clinicians (12 from Europe and 12 from North America) participated in Phase 2. A consensus-based decision analysis approach was used to identify factors (and their relative weights) that influence the probability of "developing RA," complemented by data from the Phase 1 study. Patient case scenarios were used to identify and reach consensus on factors important in determining the probability of RA development. Decision analytic software was used to derive the relative weights for each of the factors and their categories, using choice-based conjoint analysis. Results. The expert panel agreed that the new classification criteria should be applied to individuals with undifferentiated inflammatory arthritis in whom at least 1 joint is deemed by an expert assessor to be swollen, indicating definite synovitis. In this clinical setting, they identified 4 additional criteria as being important: number of joints involved and site of involvement, serologic abnormality, acute-phase response, and duration of symptoms in the involved joints. These criteria were consistent with those identified in the Phase 1 data-driven approach. Conclusion. The consensus-based, decision analysis approach used in Phase 2 complemented the Phase 1 efforts. The 4 criteria and their relative weights form the basis of the final criteria set. 
      </description>
      <author>Neogi, T.</author> <author>Aletaha, D.</author> <author>Cohen, M.D.</author> <author>Combe, B.</author> <author>Costenbader, K.H.</author> <author>Dougados, M.</author> <author>Emery, P.</author> <author>Ferraccioli, G.</author> <author>Hazes, J.M.W.</author> <author>Hobbs, K.</author> <author>Huizinga, T.W.J.</author> <author>Kavanaugh, A.</author> <author>Silman, A.J.</author> <author>Kay, J.</author> <author>Khanna, D.</author> <author>Kvien, T.K.</author> <author>Laing, T.</author> <author>Liao, K.</author> <author>Mease, P.</author> <author>Ménard, H.A.</author> <author>Moreland, L.W.</author> <author>Nair, R.</author> <author>Pincus, T.</author> <author>Naden, R.L.</author> <author>Ringold, S.</author> <author>Smolen, J.S.</author> <author>Stanislawska-Biernat, E.</author> <author>Symmons, D.</author> <author>Tak, P.P.</author> <author>Upchurch, K.S.</author> <author>Vencovský, J.</author> <author>Wolfe, F.</author> <author>Hawker, G.</author> <author>Felson, D.</author> <author>Aggarwal, R.</author> <author>Bingham, C.O.</author> <author>Birnbaum, N.S.</author> <author>Burmester, G.R.</author> <author>Bykerk, V.P.</author>
    </item> <item>
      <title>Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis (Article)</title>
      <link>http://repub.eur.nl/res/pub/28486/</link>
      <pubDate>2010-08-21T00:00:00Z</pubDate>
      <description>
        
        Introduction: The glucocorticoid receptor (GR) plays an important regulatory role in the immune system. Four polymorphisms in the GR gene are associated with differences in glucocorticoid (GC) sensitivity; the minor alleles of the polymorphisms N363 S and BclI are associated with relative hypersensitivity to GCs, while those of the polymorphisms ER22/23EK and 9β are associated with relative GC resistance. Because differences in GC sensitivity may influence immune effector functions, we examined whether these polymorphisms are associated with the susceptibility to develop Rheumatoid Arthritis (RA) and RA disease severity.Methods: The presence of GR polymorphisms was assessed in healthy controls (n = 5033), and in RA patients (n = 368). A second control group (n = 532) was used for confirmation of results. In RA patients, the relationship between GR polymorphisms and disease severity was examined.Results: Carriers of the N363 S and BclI minor alleles had a lower risk of developing RA: odds ratio (OR) = 0.55 (95% confidence interval (CI) 0.32-0.96, P = 0.032) and OR = 0.73 (95% CI 0.58-0.91, P = 0.006), respectively. In contrast, 9β minor allele carriers had a higher risk of developing RA: OR = 1.26 (95% CI 1.00-1.60, P = 0.050). For ER22/23EK minor allele carriers a trend to an increased risk OR = 1.42 (95% CI 0.95-2.13, P = 0.086) was found. All ER22/23EK carriers (32/32) had erosive disease, while only 77% (259/336) of the non-carriers did (P = 0.008). In addition, ER22/23EK carriers were treated more frequently with anti-tumor necrosis factor-alpha (TNFα) therapy (P &lt; 0.05).Conclusions: The minor alleles of the 9β and ER22/23EK polymorphisms seem to be associated with increased predisposition to develop RA. Conversely, the minor alleles of the N363 S and BclI polymorphisms are associated with reduced susceptibility to develop RA. These opposite associations suggest that constitutionally determined GC resistance may predispose to development of auto-immunity, at least in RA, and vice versa. 
      </description>
      <author>Oosten, M.J.M. van</author> <author>Dolhain, R.J.E.M.</author> <author>Koper, J.W.</author> <author>Rossum, E.F.C. van</author> <author>Emonts, M.</author> <author>Han, K.H.</author> <author>Wouters, J.M.G.W.</author> <author>Hazes, J.M.W.</author> <author>Lamberts, S.W.J.</author> <author>Feelders, R.A.</author>
    </item> <item>
      <title>A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects (Article)</title>
      <link>http://repub.eur.nl/res/pub/20328/</link>
      <pubDate>2010-06-01T00:00:00Z</pubDate>
      <description>
        
        Objective: To compare the sensitivity of autofluorescence endoscopy (AFE) and white light video endoscopy (WLE) for the detection of colorectal adenomas in high-risk patients belonging to Lynch syndrome (LS) or familial colorectal cancer (CRC) families. Methods: This was a prospective single-centre study carried out in a tertiary referral centre. The subjects were 75 asymptomatic patients originating from LS or familial CRC families. Patients were examined with either WLE followed by AFE or AFE followed by WLE. Back-to-back colonoscopy was performed by two blinded endoscopists. All lesions were removed during the second endoscopic procedure. Lesions missed during the second procedure were identified and removed on third pass. The sensitivity calculations for colorectal adenomas were based on histology results. The main outcome measures were the difference in sensitivity between WLE and AFE for the detection of adenomas in patients with LS or familial CRC. Results: At least one adenoma was detected in 41 (55%) patients. WLE identified adenomas in 28/41 patients and AFE in 37/41 patients, corresponding to a 32% increase. In total 95 adenomas were detected, 65 by WLE and 87 by AFE, resulting in a significantly higher sensitivity of AFE compared with WLE (92% vs 68%; p=0.001). The additionally detected adenomas with AFE were significantly smaller than the adenomas detected by WLE (mean 3.0 mm vs 4.9 mm, p&lt;0.01). Conclusions: AFE improves the detection of colorectal adenomas in patients with LS or familial CRC. The results of this study suggest that AFE may be preferable for surveillance of these high-risk patients.
      </description>
      <author>Ramsoekh, D.</author> <author>Haringsma, J.</author> <author>Poley, J.W.</author> <author>Putten, P. van</author> <author>Dekken, H. van</author> <author>Steyerberg, E.W.</author> <author>Leerdam, M.E. van</author> <author>Kuipers, E.J.</author>
    </item> <item>
      <title>Exploring the Public Health Impact of an Intensive Exercise Program for Patients with Rheumatoid Arthritis: A Dissemination and Implementation Study (Article)</title>
      <link>http://repub.eur.nl/res/pub/27450/</link>
      <pubDate>2010-06-01T00:00:00Z</pubDate>
      <description>
        
        Objective. To evaluate the implementation of an intensive group exercise program in patients with rheumatoid arthritis (RA). Methods. In 4 regions in The Netherlands, the Rheumatoid Arthritis Patients In Training exercise program was implemented on a limited scale. Evaluation using the RE-AIM model included: Reach, the proportion of the target population participating; Efficacy, effects on muscle strength, aerobic capacity, functional ability, and psychological functioning; Adoption, program adoption by stakeholders; Implementation, intervention quality (quality audits); and Maintenance, stakeholders' willingness to continue the program in the future. Results. Twenty-five physical therapists from 14 practices were trained to provide the program. In total, 150 RA patients were recruited (by estimation, 2% of the target population). Of the 81 patients who had finished the 12-month intervention and were available for followup directly after the intervention, 62 patients provided clinical data. Muscle strength improved significantly, whereas aerobic capacity, functional ability, psychological functioning, and disease activity did not change. All 9 informed local patient organizations facilitated patient recruitment, and 35 of 51 rheumatologists involved referred one or more patients. All 10 approached health insurance companies funded the program for 12 months. The quality audits showed sufficient quality in 9 of 12 practices. All of the providers of the program were willing to provide the program in the future, whereas future reimbursement by health insurance companies remained unclear. Conclusion. The implementation of an intensive exercise program for RA patients on a limited scale can be considered successful regarding its reach, adoption, and implementation. The limited effectiveness and the limited data regarding maintenance warrant additional research. 
      </description>
      <author>Giesen, F.J. van der</author> <author>Lankveld, W. van</author> <author>Hopman-Rock, M.</author> <author>Jong, Z. de</author> <author>Munneke, M.</author> <author>Hazes, J.M.W.</author> <author>Riel, P.L.C.M. van</author> <author>Peeters, A.J.</author> <author>Ronday, H.K.</author> <author>Vliet Vlieland, T.P.M.</author>
    </item> <item>
      <title>Spontaneous onset of Complex Regional Pain Syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/28241/</link>
      <pubDate>2010-05-01T00:00:00Z</pubDate>
      <description>
        
        Complex Regional Pain Syndrome (CRPS) usually develops after a noxious event, but spontaneous onsets have been described in 3-11% of the cases. The existence of spontaneous-onset CRPS is highly debated and the aim of the present study was therefore to compare the phenotypic characteristics of CRPS patients with a spontaneous onset, with those of patients with a trauma-induced onset. Data of 537 CRPS patients followed up at four departments of anesthesiology were analyzed and comprised 498 (93%) patients with and 39 (7%) patients without a known eliciting event. There where no significant differences between the two groups in gender, or in onset in upper or lower limb or left or right side of the body. Compared to CRPS patients with a trauma-induced onset, spontaneous-onset cases were on average 9 years younger at disease onset and had a 1.4 years longer median disease duration. No significant differences in frequency were found for any of the 34 compared signs and symptoms when the effect of multiple testing was controlled. In conclusion, CRPS may develop both with and without a precipitating noxious event, with both groups exhibiting a largely similar clinical presentation. Spontaneous-onset CRPS patients generally develop the syndrome at a younger age, possibly indicating a susceptibility to develop the condition. The longer disease duration in spontaneous-onset cases may reflect a more gradual disease onset, poorer prognosis, or a delay in diagnosis, possibly as a result of reluctance to make this diagnosis in the absence of a clear initiating event. 
      </description>
      <author>Rooij, A.M. de</author> <author>Perez, R.S.G.M.</author> <author>Huygen, F.J.P.M.</author> <author>Eijs, F.v.</author> <author>Kleef, M.v.</author> <author>Bauer, M.C.R.</author> <author>Hilten, J.J. van</author> <author>Marinus, J.</author>
    </item> <item>
      <title>Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of Interleukin-22, but not Interleukin-21, in autoimmune experimental arthritis (Article)</title>
      <link>http://repub.eur.nl/res/pub/27547/</link>
      <pubDate>2010-04-01T00:00:00Z</pubDate>
      <description>
        
        Objective. To examine the role of interleukin-23 (IL-23) in subgroup polarization of IL-17A-positive and/or interferon-γ (IFNγ)-positive T cells in autoimmune disease-prone DBA/1 mice with and without collagen-induced arthritis. Methods. A magnetic-activated cell sorting system was used to isolate CD4+ T cells from the spleen of naive and type II collagen (CII)-immunized DBA/1 mice. These CD4+ T cells were stimulated in vitro under Th0, Th1, or different Th17 culture conditions. Intracellular staining for IL-17A and IFNγ was evaluated by flow cytometry. In addition, Th17 cytokines and T helper-specific transcription factors were analyzed by enzyme-linked immunosorbent assay and/or quantitative polymerase chain reaction. Results. In CD4+ T cells from naive DBA/1 mice, IL-23 alone hardly induced retinoic acid-related orphan receptor γt (RORγt), Th17 polarization, and Th17 cytokines, but it inhibited T-bet expression. In contrast, transforming growth factor β1 (TGFβ1)/IL-6 was a potent inducer of RORγt, RORα, IL-17A, IL-17F, IL-21, and FoxP3 in these cells. In contrast to TGFβ1/IL-6, IL-23 was critical for the induction of IL-22 in CD4+ T cells from both naive and CII-immunized DBA/1 mice. Consistent with these findings, IL-23 showed a more pronounced induction of the IL-17A+IFNγ- subset in CD4+ T cells from CII-immunized mice. However, in CD4+ T cells from naive mice, IL-23 significantly increased the TGFβ1/IL-6-induced Th17 polarization, including elevated levels of IL-17A and IL-17F and decreased expression of T-bet and FoxP3. Of note, the IL-23-induced increase in IL-17A and IL-17F levels was prevented in T-bet-deficient mice. Conclusion. IL-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of IL-22, but not IL-21, levels in autoimmune arthritis. These data indicate different mechanisms for IL-23 and TGFβ1/IL-6 at the transcription factor level during Th17 differentiation in autoimmune experimental arthritis. 
      </description>
      <author>Mus, A.M.C.</author> <author>Cornelissen, F.H.J.</author> <author>Asmawidjaja, P.</author> <author>Hamburg, J.P. van</author> <author>Boon, L.</author> <author>Hendriks, R.W.</author> <author>Lubberts, E.W.</author>
    </item> <item>
      <title>When does rheumatoid arthritis start and can it be stopped before it does? (Article)</title>
      <link>http://repub.eur.nl/res/pub/27322/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>
        
        
      </description>
      <author>Bykerk, V.P.</author> <author>Hazes, J.M.W.</author>
    </item>
  </channel>
</rss>